In today’s competitive and time-sensitive environment, the ability to efficiently translate a promising molecule into a scalable, robust and regulatory-compliant process has become a key differentiator. This webinar explores how integrated CDMO strategies can help address these challenges, and attendees can register to learn how to improve development efficiency across stages.
Attendees will learn how priorities evolve from early-stage to late-stage biopharmaceutical development, including the transition from process foundation and optimization to commercial-scale readiness. The featured speakers will discuss how process understanding, Quality by Design and validation strategies support robust, consistent and regulatory-ready processes.
This webinar will illustrate how an integrated approach can be successfully applied in practice, highlighting the development of a recombinant protein vaccine produced in CHO cells. The speakers will demonstrate how early- and late-stage activities can be seamlessly aligned under compressed timelines, integrating process development, analytical strategies, manufacturing and regulatory considerations.
Register for this webinar to explore how integrated CDMO strategies can help streamline development, enhance process robustness and accelerate the path from molecule to market.
Speakers
Laura Ferrer, R&D Director, Human Health Division, HIPRA
Laura Ferrer is a dynamic R&D Executive with a PhD in Biology and a strong scientific foundation in oncological therapy. With more than 20 years at HIPRA, she has progressed from researcher and project leader in Animal Health to creating and leading the Companion Animal R&D group. Since 2022, she has served as R&D Director for Human Health, driving the development of innovative vaccines and advanced technologies such as mRNA and lipid nanoparticle formulation. She brings a proven track record in building high-performing multidisciplinary teams, steering complex projects and shaping R&D strategy in a fast-evolving biopharmaceutical environment.
Message Presenter
Iván Martínez-Monge, R&D Manager CDMO, HIPRA
Iván Martínez-Monge is an R&D Manager at HIPRA Biotech Services, where he has played a key role in the creation and development of the CDMO division. He leads R&D activities, acting as a bridge between clients and internal technical teams, and is responsible for translating complex needs into robust bioprocess solutions from early development to commercial manufacturing.
With over 10 years of experience in mammalian and microbial bioprocess development, he combines strong technical expertise with a strategic and client-oriented mindset. He has a solid understanding of the steps required to bring a biopharmaceutical product to market, from development to GMP production. His work focuses on understanding cell behavior to design efficient processes, including fed-batch and perfusion systems.
Passionate about bioprocess engineering, he is driven by innovation and continuous learning, staying up to date with emerging technologies to deliver impactful solutions in a dynamic biopharmaceutical environment.
Message PresenterWho Should Attend?
This webinar will appeal to:
- Biopharmaceutical and Biotechnology Executives responsible for development strategy
- CMC, Technical Operations and Process Development Leaders
- R&D and Program Leaders seeking reliable CDMO partners
- Decision-makers evaluating outsourcing strategies for biologics and vaccines
What You Will Learn
Attendees will:
- Understand the key differences between early-stage and late-stage biopharmaceutical development
- Learn how integrated CDMO models can accelerate development timelines
- Gain insight into how process understanding, Quality by Design and validation strategies ensure robustness and regulatory readiness at commercial scale
- Learn how an integrated development case study illustrates the acceleration of biologics development
Xtalks Partner
HIPRA
HIPRA Biotech Services is a CDMO supporting pharmaceutical and biotech companies across the full life cycle of biologic and vaccine products. Backed by over 50 years of scientific and technical excellence including our internally commercialized and marketed COVID vaccine, we offer end-to-end development and GMP manufacturing solutions across a wide range of expression platforms, from viral to mammalian to microbial platforms, to make clinical and commercial drug substance and drug product for our clients. With a team of 400+ R&D scientists and over 1,000 professionals in Manufacturing, QA and QC, state-of-the-art facilities, and a strong regulatory track record, we deliver both clinical and commercial programs with speed, quality, and flexibility. We continuously invest in innovation and capacity expansion, making us a trusted partner that will grow with our clients for their long-term success.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account